SCHEMBL4641768

SCHEMBL4641768

CC(C)(C)OC(=O)NC[C@H]1CNC[C@@H]1CNC(=O)OC(C)(C)C

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.43
EPHX1 P07099 1/20 0.43
GFER P55789 1/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
GAA P10253 2/20 0.41
DRD2 P14416 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
HCRTR2 O43614 1/20 0.38
ACACB O00763 1/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29248620 1.00 TDP1 (0.43) TDP1EPHX1GFERKMT2AMEN1
SCHEMBL4641773 1.00 TDP1 (0.43) TDP1EPHX1GFERKMT2AMEN1
SCHEMBL4641778 1.00 TDP1 (0.43) TDP1EPHX1GFERKMT2AMEN1
SCHEMBL4515883 0.91 KMT2A (0.41) TDP1EPHX1GFERKMT2AMEN1
SCHEMBL4515878 0.91 KMT2A (0.41) TDP1EPHX1GFERKMT2AMEN1
SCHEMBL27341396 0.91 KMT2A (0.41) TDP1EPHX1GFERKMT2AMEN1
SCHEMBL4515874 0.91 KMT2A (0.41) TDP1EPHX1GFERKMT2AMEN1
SCHEMBL13382322 0.89 EPHX1 (0.37) TDP1EPHX1GFERKMT2AMEN1
SCHEMBL8803829 0.89 TDP1 (0.41) TDP1EPHX1GFERKMT2AMEN1
SCHEMBL4509820 0.89 EPHX1 (0.38) TDP1EPHX1GFERKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0934924-B1 NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO (JP) 2008-08-13 EP disclosed
US-6576642-B2 Inhibitors of the production of Ig E antibodies, antiallergens KOWA CO., LTD. (JP) 2003-06-10 US disclosed
US-20010039279-A1 Diamide compounds and compositions containing the same KOWA CO., LTD. (JP) 2001-11-08 US disclosed
US-6297283-B1 EXCELLENT INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY AND ARE HENCE USEFUL AS ANTIALLERGIC AGENTS KOWA CO., LTD. (JP) 2001-10-02 US disclosed
EP-0934924-A1 NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO. LTD. (JP) 1999-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039279-A1 Diamide compounds and compositions containing the same HRH4, HRH2, HRH1 TDP1 3639/4885EPHX1 1236/4885GFER 2286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.